Full Text of HB4628 103rd General Assembly
HB4628 103RD GENERAL ASSEMBLY | | | 103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024 HB4628 Introduced 1/31/2024, by Rep. Jawaharial Williams SYNOPSIS AS INTRODUCED: | | 720 ILCS 570/208 | from Ch. 56 1/2, par. 1208 |
| Amends the Illinois Controlled Substances Act. Schedules Tianeptine as a Schedule III controlled substance. |
| |
| | A BILL FOR |
| | | | HB4628 | | LRB103 35592 RLC 65665 b |
|
| 1 | | AN ACT concerning criminal law. | 2 | | Be it enacted by the People of the State of Illinois, | 3 | | represented in the General Assembly: | 4 | | Section 5. The Illinois Controlled Substances Act is | 5 | | amended by changing Section 208 as follows: | 6 | | (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208) | 7 | | Sec. 208. (a) The controlled substances listed in this | 8 | | Section are included in Schedule III. | 9 | | (b) Unless specifically excepted or unless listed in | 10 | | another schedule, any material, compound, mixture, or | 11 | | preparation which contains any quantity of the following | 12 | | substances having a stimulant effect on the central nervous | 13 | | system, including its salts, isomers (whether optical | 14 | | position, or geometric), and salts of such isomers whenever | 15 | | the existence of such salts, isomers, and salts of isomers is | 16 | | possible within the specific chemical designation; | 17 | | (1) Those compounds, mixtures, or preparations in | 18 | | dosage unit form containing any stimulant substances | 19 | | listed in Schedule II which compounds, mixtures, or | 20 | | preparations were listed on August 25, 1971, as excepted | 21 | | compounds under Title 21, Code of Federal Regulations, | 22 | | Section 308.32, and any other drug of the quantitative | 23 | | composition shown in that list for those drugs or which is |
| | | HB4628 | - 2 - | LRB103 35592 RLC 65665 b |
|
| 1 | | the same except that it contains a lesser quantity of | 2 | | controlled substances; | 3 | | (2) Benzphetamine; | 4 | | (3) Chlorphentermine; | 5 | | (4) Clortermine; | 6 | | (5) Phendimetrazine ; . | 7 | | (6) Tianeptine. | 8 | | (c) Unless specifically excepted or unless listed in | 9 | | another schedule, any material, compound, mixture, or | 10 | | preparation which contains any quantity of the following | 11 | | substances having a potential for abuse associated with a | 12 | | depressant effect on the central nervous system: | 13 | | (1) Any compound, mixture, or preparation containing | 14 | | amobarbital, secobarbital, pentobarbital or any salt | 15 | | thereof and one or more other active medicinal ingredients | 16 | | which are not listed in any schedule; | 17 | | (2) Any suppository dosage form containing | 18 | | amobarbital, secobarbital, pentobarbital or any salt of | 19 | | any of these drugs and approved by the Federal Food and | 20 | | Drug Administration for marketing only as a suppository; | 21 | | (3) Any substance which contains any quantity of a | 22 | | derivative of barbituric acid, or any salt thereof: | 23 | | (3.1) Aprobarbital; | 24 | | (3.2) Butabarbital (secbutabarbital); | 25 | | (3.3) Butalbital; | 26 | | (3.4) Butobarbital (butethal); |
| | | HB4628 | - 3 - | LRB103 35592 RLC 65665 b |
|
| 1 | | (4) Chlorhexadol; | 2 | | (5) Methyprylon; | 3 | | (6) Sulfondiethylmethane; | 4 | | (7) Sulfonethylmethane; | 5 | | (8) Sulfonmethane; | 6 | | (9) Lysergic acid; | 7 | | (10) Lysergic acid amide; | 8 | | (10.1) Tiletamine or zolazepam or both, or any salt of | 9 | | either of them. | 10 | | Some trade or other names for a tiletamine-zolazepam
| 11 | | combination product: Telazol.
| 12 | | Some trade or other names for Tiletamine:
| 13 | | 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
| 14 | | Some trade or other names for zolazepam:
| 15 | | 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
| 16 | | [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon. | 17 | | (11) Any material, compound, mixture or preparation | 18 | | containing not more than 12.5 milligrams of pentazocine or | 19 | | any of its salts, per 325 milligrams of aspirin; | 20 | | (12) Any material, compound, mixture or preparation | 21 | | containing not more than 12.5 milligrams of pentazocine or | 22 | | any of its salts, per 325 milligrams of acetaminophen; | 23 | | (13) Any material, compound, mixture or preparation | 24 | | containing not more than 50 milligrams of pentazocine or | 25 | | any of its salts plus naloxone HCl USP 0.5 milligrams, per | 26 | | dosage unit; |
| | | HB4628 | - 4 - | LRB103 35592 RLC 65665 b |
|
| 1 | | (14) Ketamine; | 2 | | (15) Thiopental. | 3 | | (d) Nalorphine. | 4 | | (d.5) Buprenorphine. | 5 | | (e) Unless specifically excepted or unless listed in | 6 | | another schedule, any material, compound, mixture, or | 7 | | preparation containing limited quantities of any of the | 8 | | following narcotic drugs, or their salts calculated as the | 9 | | free anhydrous base or alkaloid, as set forth below: | 10 | | (1) not more than 1.8 grams of codeine per 100 | 11 | | milliliters or not more than 90 milligrams per dosage | 12 | | unit, with an equal or greater quantity of an isoquinoline | 13 | | alkaloid of opium; | 14 | | (2) not more than 1.8 grams of codeine per 100 | 15 | | milliliters or not more than 90 milligrams per dosage | 16 | | unit, with one or more active non-narcotic ingredients in | 17 | | recognized therapeutic amounts; | 18 | | (3) (blank); | 19 | | (4) (blank); | 20 | | (5) not more than 1.8 grams of dihydrocodeine per 100 | 21 | | milliliters or not more than 90 milligrams per dosage | 22 | | unit, with one or more active, non-narcotic ingredients in | 23 | | recognized therapeutic amounts; | 24 | | (6) not more than 300 milligrams of ethylmorphine per | 25 | | 100 milliliters or not more than 15 milligrams per dosage | 26 | | unit, with one or more active, non-narcotic ingredients in |
| | | HB4628 | - 5 - | LRB103 35592 RLC 65665 b |
|
| 1 | | recognized therapeutic amounts; | 2 | | (7) not more than 500 milligrams of opium per 100 | 3 | | milliliters or per 100 grams, or not more than 25 | 4 | | milligrams per dosage unit, with one or more active, | 5 | | non-narcotic ingredients in recognized therapeutic | 6 | | amounts; | 7 | | (8) not more than 50 milligrams of morphine per 100 | 8 | | milliliters or per 100 grams with one or more active, | 9 | | non-narcotic ingredients in recognized therapeutic | 10 | | amounts. | 11 | | (f) Anabolic steroids, except the following anabolic | 12 | | steroids that are exempt: | 13 | | (1) Androgyn L.A.; | 14 | | (2) Andro-Estro 90-4; | 15 | | (3) depANDROGYN; | 16 | | (4) DEPO-T.E.; | 17 | | (5) depTESTROGEN; | 18 | | (6) Duomone; | 19 | | (7) DURATESTRIN; | 20 | | (8) DUO-SPAN II; | 21 | | (9) Estratest; | 22 | | (10) Estratest H.S.; | 23 | | (11) PAN ESTRA TEST; | 24 | | (12) Premarin with Methyltestosterone; | 25 | | (13) TEST-ESTRO Cypionates; | 26 | | (14) Testosterone Cyp 50 Estradiol Cyp 2; |
| | | HB4628 | - 6 - | LRB103 35592 RLC 65665 b |
|
| 1 | | (15) Testosterone Cypionate-Estradiol Cypionate | 2 | | injection; and | 3 | | (16) Testosterone Enanthate-Estradiol Valerate | 4 | | injection. | 5 | | (g) Hallucinogenic substances. | 6 | | (1) Dronabinol (synthetic) in sesame oil and | 7 | | encapsulated in a soft gelatin capsule in a U.S. Food and | 8 | | Drug Administration approved product. Some other names for | 9 | | dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- | 10 | | 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or | 11 | | (-)-delta-9-(trans)-tetrahydrocannabinol. | 12 | | (2) (Reserved). | 13 | | (h) The Department may except by rule any compound, | 14 | | mixture, or preparation containing any stimulant or depressant | 15 | | substance listed in subsection (b) from the application of all | 16 | | or any part of this Act if the compound, mixture, or | 17 | | preparation contains one or more active medicinal ingredients | 18 | | not having a stimulant or depressant effect on the central | 19 | | nervous system, and if the admixtures are included therein in | 20 | | combinations, quantity, proportion, or concentration that | 21 | | vitiate the potential for abuse of the substances which have a | 22 | | stimulant or depressant effect on the central nervous system. | 23 | | (Source: P.A. 100-368, eff. 1-1-18 .) |
|